Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.

NCT01641107 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01641107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01641107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
December 4, 2014
Completion date
September 30, 2021
Enrollment
44 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, bcr-abl positive, philadelphia positive